Breakthrough Discovery at NUS Medicine Unlocks Potential to Reverse Brain Aging

Singapore's National University of Singapore (NUS) has emerged at the forefront of neuroscience research with a groundbreaking study revealing the role of the DMTF1 protein in rejuvenating aging brain cells. Researchers from the Yong Loo Lin School of Medicine identified that upregulating cyclin D-binding Myb-like transcription factor 1 (DMTF1), a key transcription factor, can restore the proliferative capacity of neural stem cells (NSCs) impaired by age-related telomere dysfunction. This finding, published in the prestigious journal Science Advances on January 2, 2026, highlights NUS's commitment to tackling global challenges like population aging through innovative higher education research.

Led by Assistant Professor Ong Sek Tong Derrick and first author Dr. Liang Yajing from the Department of Physiology, the study utilized advanced models of premature aging to demonstrate how DMTF1 acts as a molecular switch for NSC regeneration. As Singapore grapples with a rapidly aging society—projected to have nearly one in four residents over 65 by 2030—this research positions NUS as a hub for translational neuroscience.

Neural Stem Cells: Guardians of Brain Plasticity and Victims of Aging

Neural stem cells (NSCs), multipotent cells residing primarily in the subventricular zone (SVZ) of the lateral ventricles and the subgranular zone (SGZ) of the dentate gyrus in the hippocampus, are essential for adult neurogenesis—the process by which new neurons are generated throughout life. These cells self-renew and differentiate into neurons, astrocytes, and oligodendrocytes, supporting learning, memory, and cognitive flexibility.

However, with advancing age, NSC proliferation and activation decline dramatically. In humans, this manifests as reduced hippocampal neurogenesis, contributing to cognitive impairments seen in 20-30% of individuals over 70. Factors like telomere attrition—shortening of chromosome end-caps that triggers cellular senescence—exacerbate this, mimicking premature aging in telomerase-deficient models used in the NUS study. The research team's use of late-generation telomerase reverse transcriptase (TERT) knockout mice (G4 TERT^ER/ER) provided a precise model to dissect these mechanisms.

Unraveling DMTF1: From Cancer Regulator to Neuroregenerative Hero

Cyclin D-binding Myb-like transcription factor 1 (DMTF1) was previously known primarily for its tumor-suppressive role, where it activates the Arf/p53 pathway to halt aberrant cell proliferation in cancers like breast and lung tumors. Surprisingly, in the context of NSCs, DMTF1 exhibits a pro-proliferative function. The NUS team discovered that DMTF1 expression is significantly downregulated in telomere-dysfunctional NSCs, both in mouse models and human neural progenitor cells (hNPCs) derived from TERT-deficient human embryonic stem cells (hESCs).

• DMTF1 levels drop in aged SVZ and dentate gyrus NSCs, correlating with reduced neurogenesis.
• Forced overexpression of wild-type DMTF1 (but not domain mutants lacking cyclin D-binding or Myb DNA-binding regions) fully rescues proliferation defects, increasing BrdU incorporation by up to 3-fold and restoring markers like MCM2 without lengthening telomeres.
• Conversely, DMTF1 knockdown via shRNA or CRISPR induces G1 cell cycle arrest, apoptosis (elevated cleaved caspase-3), and reduced neurosphere formation in organoids.

This duality underscores DMTF1's context-dependent role, promoting healthy proliferation while suppressing oncogenesis—a nuance critical for therapeutic development.

Innovative Methods Powering the NUS Breakthrough

The study's rigor stems from multifaceted approaches blending in vivo, in vitro, and human-relevant models. Mouse NSCs were isolated from embryonic cortices and cultured in EGF/FGF media to induce proliferation. Human models included cortical organoids and hNPCs, ensuring translatability. Key techniques included:

• ChIP-seq for DMTF1 binding, revealing promoter-enriched peaks in chromatin organization genes.
• RNA-seq identifying 1766 downregulated genes upon DMTF1 depletion, enriched for E2F1 targets.
• Western blots, immunofluorescence (IF), and flow cytometry for proliferation (Ki67/BrdU/EdU), DNA damage (γH2AX), and stemness (SOX2/Nestin) markers.
• Luciferase assays confirming DMTF1's direct activation of Ss18 promoter via GGCGGCGG motif.

These methods not only validated causality but also mapped epigenetic changes like H3K27ac deposition.Read the full Science Advances paper.

The SWI/SNF-E2F Axis: DMTF1's Molecular Machinery

At the heart of the discovery is DMTF1's transcriptional activation of Arid2 (PBAF subunit) and Ss18 (cBAF/ncBAF subunit), core components of the SWI/SNF chromatin remodeling complexes. These complexes reposition nucleosomes to facilitate histone acetylation (H3K27ac), opening chromatin at E2F1/E2F4 target promoters for genes driving cell cycle (Plk1, Mad2l1, Iqgap3) and DNA replication (Mcm2/6).

• DMTF1 depletion reduces Arid2/Ss18 expression and binding, slashing H3K27ac levels and boosting repressive H3K27me3.
• Arid2 or Ss18 knockdown phenocopies DMTF1 loss, blocking rescue by DMTF1 overexpression.
• Integrated genomics showed colocalization of DMTF1, SWI/SNF subunits, and E2Fs at shared loci.

This pathway elucidates how DMTF1 counters aging-induced epigenetic silencing, offering a blueprint for interventions.

Photo by Nathan Rimoux on Unsplash

Therapeutic Horizons: Combating Neurodegeneration

The implications extend to age-related diseases like Alzheimer's, Parkinson's, and vascular dementia, where NSC exhaustion underlies neuronal loss. By targeting DMTF1—potentially via small molecules or gene therapy—clinicians could boost endogenous neurogenesis, enhancing cognitive reserve. Dr. Liang notes, "Our findings suggest that DMTF1 can contribute to neural stem cell multiplication in neurological aging."

However, challenges remain: balancing proliferation without glioma risk (DMTF1 upregulated in glioblastoma multiforme) and validating in naturally aged mice for neurogenesis and behavior (e.g., Morris water maze). NUS's Healthy Longevity Programme positions it ideally for these next steps.NUS Medicine press release.

Singapore's Research Ecosystem Fuels NUS Excellence

Singapore's S$37 billion Research, Innovation, and Enterprise 2030 (RIE2030) plan, launched in December 2025, allocates significant funds to healthy longevity, semiconductors, and AI—domains intersecting neuroscience. NUS benefits from this, alongside NTU and A*STAR, fostering interdisciplinary hubs. The Healthy Longevity Translational Research Programme at NUS Medicine exemplifies this, integrating physiology, cancer research, and stem cell biology.

This ecosystem attracts global talent, with initiatives like the NUS Graduate School for Integrative Sciences and Engineering offering PhD opportunities. For aspiring researchers, explore higher ed research jobs or Singapore academic positions to contribute to such breakthroughs.

Stakeholder Perspectives and Broader Impacts

Asst Prof Ong emphasizes, "Understanding the mechanisms for neural stem cell regeneration provides a stronger foundation for studying age-related cognitive decline." Industry experts hail the epigenetic focus as novel, potentially synergizing with senolytics or Yamanaka factors. Policymakers in Singapore view it as bolstering the nation's biomedical hub status, amid rising dementia cases (over 82,000 in 2025, doubling by 2030).

Stakeholders include patients, neuroscientists, and ethicists concerned with off-target effects. Balanced views stress rigorous in vivo testing before trials.

Navigating Challenges Toward Clinical Translation

Key hurdles: DMTF1's cancer duality necessitates conditional activation (e.g., NSC-specific promoters). Delivery challenges for brain-penetrant small molecules persist, though CRISPR-based editing shows promise. Future studies must assess long-term safety in primates and humans.

• Risks: Hyperproliferation leading to tumors—mitigated by p53 co-regulation.
• Solutions: Combination therapies with anti-senescents; AI-optimized compounds via NUS's computational biology.
• Timeline: Preclinical in aged mice (1-2 years), IND filing (3-5 years).

Singapore's regulatory agility via HSA accelerates this.

Career Pathways in Singapore's Neuroscience Boom

This discovery spotlights opportunities at NUS and beyond. Postdoctoral roles in stem cell epigenetics abound, with salaries averaging S$60,000-90,000. Faculty positions emphasize translational impact, aligning with RIE2030 grants.

Prospective academics can leverage higher ed career advice, free resume templates, and platforms like Rate My Professor. Explore postdoc jobs, research assistant roles, or faculty openings in Singapore's universities. For employers, academic recruitment services connect top talent.

Photo by Alexander K on Unsplash

Future Outlook: A New Era for Brain Health Research

The DMTF1 breakthrough heralds a paradigm shift, potentially extending healthy lifespan via NSC rejuvenation. NUS's leadership, backed by national investment, promises rapid progress. Researchers worldwide are inspired to pursue similar epigenetic levers.

Stay engaged with Singapore higher ed innovations via university jobs, higher ed jobs, and career advice. Share your insights in the comments below and position yourself at the forefront of neuroscience.